Business
Driven by a common vision, Mochida Pharmaceutical Co., Ltd. and Duchesnay Inc. sign a partnership to help address the issue of drug gap in Japan
Mochida Pharmaceutical Co., Ltd. (Head Office: Shinjuku-ku, Tokyo, Japan; President: Naoyuki Mochida; hereinafter "Mochida") and Duchesnay Inc. (Head Office: Quebec, Canada; President: Éric Gervais; hereinafter "Duchesnay") announce that they have entered into a license agreement to provide access to Bonjesta® (hereinafter "the product") in Japan. Under this agreement, the companies will collaborate closely with the objective of making this product available for women in Japan, with Mochida cond
About this update from Mochida Pharmaceutical Co., Ltd.
[{"type":"text","content":"BLAINVILLE, QC, Dec. 15, 2025 /CNW/ - Mochida Pharmaceutical Co., Ltd. (Head Office: Shinjuku-ku, Tokyo, Japan; President: Naoyuki Mochida; hereinafter "Mochida") and Duchesnay Inc. (Head Office: Quebec, Canada; President: Éric Gervais; hereinafter "Duchesnay") announce that they have entered into a license agreement to provide access to Bonjesta® (hereinafter "the product") in Japan. Under this agreement, the companies will collaborate closely with the objective of making this product available for women in Japan, with Mochida conducting the necessary research activities required to obtain regulatory approval from the Pharmaceuticals and Medical Devices Agency (PMDA).","length":717,"tagName":"p"},{"type":"image","alt":"Duchesnay Inc. (CNW Group/Duchesnay Inc.)","displaySize":"","headline":null,"caption":"Duchesnay Inc. (CNW Group/Duchesnay Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":142,"url":"https://media.zenfs.com/en/cnwgroup.com/0b18156e908e87c28f9cc6433e405e3d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Ke19Uyj0DAQl74HuBBFMpA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI1MDtjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/0b18156e908e87c28f9cc6433e405e3d","width":400,"height":142}},"href":"https://mma.prnewswire.com/media/2844613/Duchesnay_Inc__Driven_by_a_common_vision_%C2%A0Mochida_Pharmaceutical.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Bonjesta® is a formulation developed by Duchesnay to manage nausea and vomiting of pregnancy (NVP), a common condition affecting more than half of Japanese pregnant women1) for which there are no approved medications in Japan.","length":226,"tagName":"p"},{"type":"text","content":"Recently, the Ministry of Health, Labour and Welfare of Japan has called for companies to develop this product following a request from the Japan Society of Obstetrics and Gynecology to address the issue of "drug loss", a situation where drugs approved in Europe and the United States are not developed in Japan.","length":322,"tagName":"p"},{"type":"text","content":"The product, an oral combination formulation containing doxylamine succinate and pyridoxine hydrochloride as active ingredients, is approved in 43 countries and states worldwide, namely in the USA following FDA approval in 2...